Federal Research and Development (R&D) Funding: FY2021 (CRS Report for Congress)
Premium Purchase PDF for $24.95 (81 pages)
add to cart or
subscribe for unlimited access
Pro Premium subscribers have free access to our full library of CRS reports.
Subscribe today, or
request a demo to learn more.
Release Date |
Revised Dec. 17, 2020 |
Report Number |
R46341 |
Report Type |
Report |
Authors |
John F. Sargent Jr., Genevieve K. Croft, Robert Esworthy, Marcy E. Gallo, Laurie A. Harris, Eva Lipiec, Daniel Morgan, Kavya Sekar |
Source Agency |
Congressional Research Service |
Older Revisions |
-
Premium Revised Nov. 30, 2020 (80 pages, $24.95)
add
-
Premium Revised Sept. 2, 2020 (74 pages, $24.95)
add
-
Premium April 30, 2020 (68 pages, $24.95)
add
|
Summary:
President Trump's budget request for FY2021 includes approximately $142.2 billion for research and development (R&D) for FY2021, $13.8 billion (8.8%) below the FY2020 enacted level of $156.0 billion. In constant FY2020 dollars, the President's FY2021 R&D request would result in a decrease of $16.6 billion (10.6%) from the FY2020 level.
Federal Research and Development
Funding, FY2019-FY2021
In billions of dollars
/
Source: CRS analysis of data from OMB, Analytical Perspectives, Budget of the United States Government, Fiscal Year 2021, Research and Development, February 10, 2020.
In 2017, the Office of Management and Budget (OMB) adopted a change to the definition of development, applying a more narrow treatment that it describes as "experimental development." This change was intended to harmonize the reporting of U.S. R&D funding data with the approach used by other nations. The new definition is used in this report.
Funding for R&D is concentrated in a few departments and agencies. In FY2020, five federal agencies received 93.2% of total federal R&D funding, with the Department of Defense (DOD, 41.4%) and the Department of Health and Human Services (HHS, 26.2%) combined accounting for more than two-thirds of all federal R&D funding. In the FY2021 request, the top five R&D agencies would account for 93.8%, with DOD accounting for 42.1% and HHS for 26.6%.
Under the President's FY2021 budget request, nearly all federal agencies would see their R&D funding decline relative to FY2020. The only exception is the Department of Veterans Affairs, which would increase by $38 million (2.9%) in FY2021 to $1.351 billion. The largest dollar reductions in R&D funding would be made to the DOD (down $4.713 billion), the Department of Energy (down $3.168 billion), and HHS (down $2.843 billion). The largest percentage declines in R&D funding would be at the Department of Transportation (down 47.6%), the Environmental Protection Agency (down 35.4%), and Department of the Interior (down 25.5%)
The President's FY2021 budget request would reduce funding for basic research by $2.822 billion (6.5%), applied research by $5.125 billion (11.7%), development by $3.466 billion (5.5%), and facilities and equipment by $2.375 billion (39.6%).
Several multiagency R&D initiatives continue under the President's FY2021 budget. Some activities supporting these initiatives are discussed in agency budget justifications and are reported in the agency analyses in this report. However, comprehensive aggregate budget information on these initiatives will likely not be available until budget supplements for each are released later in the year.
The request represents the President's R&D priorities. Congress may opt to agree with none, part, or all of the request, and it may express different priorities through the appropriations process. In recent years, Congress has completed the annual appropriations process after the start of the fiscal year. Completing the process after the start of the fiscal year and the accompanying use of continuing resolutions can affect agencies' execution of their R&D budgets, including the delay or cancellation of planned R&D activities and the acquisition of R&D-related equipment.
It is not yet clear how the national response to the Coronavirus Disease 2019 (COVID-19) pandemic will affect Administration and congressional priorities for FY2021 R&D funding, or the congressional authorization and appropriations processes for enacting that funding.